15 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityBody Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorderRecruitingPhase 32026-10-08NCT07794579
Psoriasis Longitudinal Assessment and RegistrySkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderActive, not recruitingNot stated2026-09-25NCT00508547
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Diseasecardiovascular disorder, hypertensive disorder, vascular disorderRecruitingPhase 32026-09-18NCT07181109
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Disorders of Excessive Somnolence, Dyssomnias, Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, idiopathic hypersomnia, nervous system disorder, psychiatric disorder, sleep-wake disorderRecruitingPhase 32026-09-14NCT07500090
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyCataplexy, Disorders of Excessive Somnolence, Dyssomnias, Ehlers-Danlos syndrome, Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, narcolepsy, nervous system disorder, psychiatric disorder, sleep-wake disorderRecruitingPhase 32026-08-27NCT07675135
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseArterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorderActive, not recruitingPhase 32026-08-25NCT05030428
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 32026-08-14NCT05869903
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitusActive, not recruitingPhase 32026-07-31NCT06993792
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutritionActive, not recruitingPhase 32026-07-29NCT06972459
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLSDyssomnias, Parasomnias, Sleep Disorders, Intrinsic, nervous system disorder, psychiatric disorder, restless legs syndrome, sleep-wake disorderActive, not recruitingNot stated2026-05-27NCT06076499
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitusActive, not recruitingPhase 32026-04-20NCT06972472
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseChronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorderRecruitingPhase 22026-03-11NCT06717698
Clinical Data Registry of Amblyopia Patients on Luminopia TreatmentNeurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, amblyopia, brain disorder, central nervous system disorder, eye disorder, nervous system disorder, vision disorderRecruitingNot stated2025-09-12NCT06429280
Continuation Protocol for Obstructive Sleep Apnea (OSA)Apnea, Dyssomnias, Respiration Disorders, Sleep Disorders, Intrinsic, nervous system disorder, obstructive sleep apnea syndrome, respiratory system disorder, sleep apnea syndrome, sleep-wake disorderEnrolling by invitationPhase 32025-05-13NCT06566820
Observational Study to Evaluate the STALIF® C FLX, STALIF® M FLX, STALIF® L FLX Cages and FORTOS-C®Degenerative Cervical Disc Disease; Degenerative Lumbar DiseasesActive, not recruitingNot stated2025-03-14NCT06876311